Compare NRT & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NRT | FLNA |
|---|---|---|
| Founded | 1975 | 1998 |
| Country | United States | United States |
| Employees | N/A | 20 |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.7M | 61.8M |
| IPO Year | 1995 | N/A |
| Metric | NRT | FLNA |
|---|---|---|
| Price | $7.79 | $1.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 60.2K | ★ 362.2K |
| Earning Date | 05-29-2026 | 05-13-2026 |
| Dividend Yield | ★ 10.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.88 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.76 | $1.16 |
| 52 Week High | $10.49 | $2.03 |
| Indicator | NRT | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 45.38 | 44.86 |
| Support Level | $7.64 | $1.16 |
| Resistance Level | $8.68 | $1.80 |
| Average True Range (ATR) | 0.37 | 0.10 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 45.16 | 32.45 |
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.